Cardiac tissue engineering for the treatment of hypoplastic left heart syndrome (HLHS).

Cardiac tissue engineering for the treatment of hypoplastic left heart syndrome (HLHS).
复制标题

DOI:
10.21037/tp-23-127
复制
发表时间:
2023-08-30
影响因子:
2
通讯作者:
--
中科院分区:
医学4区
文献类型:
--
作者:

文献摘要

参考文献

相似文献

左心发育不良综合征(HLHS)是一种致命的先天性心脏病,当左心室和流出道未能适当发育时,会抑制身体其他部位的充分灌注。从历史上看,这种疾病已经通过一系列手术来治疗,这些手术允许心脏使用单个心室。这些手术通常是一种姑息性措施,心脏移植是这种情况下唯一确定的治疗方法。据推测,基于干细胞的再生疗法可能在促进正在接受姑息手术的HLHS患者的心脏组织再生方面发挥作用。一些临床试验已经证明,将多能细胞引入心脏是安全、可行的,并且能够改善右心室射血分数(RVEF)。然而,虽然这些方法显示出巨大的希望,但仍有发展空间。有大量的临床前工作集中在以心脏补片的形式产生越来越大和复杂的心脏组织块,其想法是这些可以用于以稳健和持久的方式重建和加强心脏。总的来说,基于干细胞的疗法在改善HLHS的治疗方面有很大的作用。
Hypoplastic left heart syndrome (HLHS) is a deadly congenital heart disease that arises when the left ventricle and outflow tract fail to develop appropriately, inhibiting the adequate perfusion of the rest of the body. Historically, this disease has been treated via a series of surgeries that allows the heart to use a single ventricle. These surgeries are often a palliative measure, and heart transplantation is the only definitive therapy that exists for this condition. It has been hypothesized that stem cell-based regenerative therapies could have a role in promoting cardiac tissue regeneration in HLHS patients who are undergoing palliative surgery. Several clinical trials have demonstrated that introducing pluripotent cells into the heart is safe, feasible, and capable of improving right ventricular ejection fraction (RVEF). However, while these approaches show great promise, there is still room for development. There is a substantial body of pre-clinical work that is focused on generating increasingly large and complex pieces of cardiac tissue in the form of cardiac patches, with the idea that these could be used to rebuild and strengthen the heart in a robust and long-lasting manner. In total, stem cell-based therapies have much to offer when it comes to improving the treatment of HLHS.
DOI: 10.3389/fped.2021.635776
发表时间: 2021
影响因子: 2.6
作者:
Best KE;Miller N;Draper E;Tucker D;Luyt K;Rankin J
通讯作者: Rankin J
DOI: 10.3390/biomedicines9050478
发表时间: 2021-04-27
期刊: Biomedicines
影响因子: 4.7
作者:
Matsuzaki Y;Wiet MG;Boe BA;Shinoka T
通讯作者: Shinoka T
DOI: 10.3389/fcvm.2020.610364
发表时间: 2020
影响因子: 3.6
作者:
Mei X;Cheng K
通讯作者: Cheng K
DOI: 10.5966/sctm.2014-0195
发表时间: 2015-02-01
影响因子: 6
作者:
Peral, Susana Cantero;Burkhart, Harold M.;Nelson, Timothy J.
通讯作者: Nelson, Timothy J.
DOI: 10.1542/pir.2018-0005
发表时间: 2019-07-01
影响因子: 1.3
作者:
Javed, Rabia;Cetta, Frank;Qureshi, Muhammad Yasir
通讯作者: Qureshi, Muhammad Yasir